His scientific interests lie mostly in Immunology, Immunotherapy, Melanoma, Immune checkpoint and Cancer research. His research investigates the connection between Immunology and topics such as Cytotoxic T cell that intersect with problems in T cell and Myeloid-derived Suppressor Cell. His work deals with themes such as Endogenous retrovirus and Immunogenicity, which intersect with Immunotherapy.
Taha Merghoub combines subjects such as MEK inhibitor, MAPK/ERK pathway, V600E and Checkpoint Blockade Immunotherapy with his study of Melanoma. His research in Immune checkpoint intersects with topics in Interferon, Interferon type I and Cancer immunotherapy. His Cancer research research is multidisciplinary, incorporating perspectives in Transcription, Repressor and Innate immune system, Innate lymphoid cell.
The scientist’s investigation covers issues in Cancer research, Immunology, Immune system, Immunotherapy and T cell. Taha Merghoub studies Cancer research, namely Melanoma. Immunology is closely attributed to Cytotoxic T cell in his work.
His Immunotherapy study combines topics from a wide range of disciplines, such as Lung cancer, Myeloid-derived Suppressor Cell, KRAS and Immunogenicity. His T cell research incorporates themes from Priming and Cell biology. His Immune checkpoint study deals with Oncolytic virus intersecting with Intratumoral Therapy.
His primary scientific interests are in Cancer research, Immunotherapy, Immune checkpoint, Immune system and T cell. His Cancer research research focuses on Melanoma in particular. Taha Merghoub interconnects Cancer cell and Vaccinia in the investigation of issues within Immune checkpoint.
His work on CD8 as part of general Immune system study is frequently linked to Population, therefore connecting diverse disciplines of science. His research on CD8 concerns the broader Immunology. The T cell study combines topics in areas such as Innate immune system, Antigen, Immunogenicity and Cancer immunotherapy.
Immunotherapy, Cancer research, Blockade, CD8 and Immune system are his primary areas of study. The various areas that he examines in his Immunotherapy study include T cell, Lung cancer, Oncology and Immunogenicity. His Cancer research study incorporates themes from Tumor microenvironment, Downregulation and upregulation, Antigen and Mutation.
His Blockade research includes themes of Neoadjuvant therapy, Major Pathologic Response, Carcinoma, T-cell receptor and Biomarker. Specifically, his work in Immune system is concerned with the study of Immune checkpoint. His Immune checkpoint study combines topics in areas such as Non small cell, Cell and Long term response.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg.
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan.
The New England Journal of Medicine (2014)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli;Pamela L. Strissel;Alexis Desrichard;Huili Li.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou.
The New England Journal of Medicine (2018)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila.
Journal of Clinical Oncology (2018)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada;Tyler R. Simpson;Karl S. Peggs;Taha Merghoub.
Journal of Experimental Medicine (2010)
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Vinod P. Balachandran;Marta Łuksza;Julia N. Zhao;Vladimir Makarov.
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Matthew D. Hellmann;Tavi Nathanson;Hira Rizvi;Benjamin C. Creelan.
Cancer Cell (2018)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin;Dmitriy Zamarin;Rikke B. Holmgaard;Rikke B. Holmgaard;Sumit K. Subudhi;Joon Seok Park;Joon Seok Park.
Science Translational Medicine (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: